Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

• Published in: International journal of molecular sciences Vol. 23; no. 18; p. 10946
• Main Authors: Ruder, Josefine, Dinner, Gianna, Maceski, Aleksandra, Berenjeno-Correa, Ernesto, Müller, Antonia Maria, Jelcic, Ilijas, Kuhle, Jens, Martin, Roland
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.09.2022; MDPI
• Subjects: Astrocytes; Autografts; autologous hematopoietic stem cell transplantation; Biomarkers; CD4 antigen; Cell activation; Central nervous system; Cerebrospinal fluid; Chemokines; Chemotherapy; Chitinase; CXCL10 protein; CXCL13 protein; Cytomegalovirus; Disease; Effector cells; Enzyme-linked immunosorbent assay; Epstein-Barr virus; Glial cells; Glial fibrillary acidic protein; Immune system; Immunological memory; Inflammation; Lymphocytes; Lymphocytes T; Memory cells; Multiple sclerosis; Neurodegeneration; Neuronal-glial interactions; Neurotoxicity; Pathophysiology; Patients; Phenotypes; Proteins; Stem cell transplantation; Stem cells; Transplantation; Viral infections
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms231810946

Autologous hematopoietic stem cell transplantation (aHSCT) is a highly efficient treatment of multiple sclerosis (MS), and hence it likely normalizes pathological and/or enhances beneficial processes in MS. The disease pathomechanisms include neuroinflammation, glial cell activation and neuronal damage. We studied biomarkers that in part reflect these, like markers for neuroinflammation (C-X-C motif chemokine ligand (CXCL) 9, CXCL10, CXCL13, and chitinase 3-like 1 (CHI3L1)), glial perturbations (glial fibrillary acidic protein (GFAP) and in part CHI3L1), and neurodegeneration (neurofilament light chain (NfL)) by enzyme-linked immunosorbent assays (ELISA) and single-molecule array assay (SIMOA) in the serum and cerebrospinal fluid (CSF) of 32 MS patients that underwent aHSCT. We sampled before and at 1, 3, 6, 12, 24 and 36 months after aHSCT for serum, as well as before and 24 months after aHSCT for CSF. We found a strong increase of serum CXCL10, NfL and GFAP one month after the transplantation, which normalized one and two years post-aHSCT. CXCL10 was particularly increased in patients that experienced reactivation of cytomegalovirus (CMV) infection, but not those with Epstein-Barr virus (EBV) reactivation. Furthermore, patients with CMV reactivation showed increased Th1 phenotype in effector memory CD4+ T cells. Changes of the other serum markers were more subtle with a trend for an increase in serum CXCL9 early post-aHSCT. In CSF, GFAP levels were increased 24 months after aHSCT, which may indicate sustained astroglia activation 24 months post-aHSCT. Other CSF markers remained largely stable. We conclude that MS-related biomarkers indicate neurotoxicity early after aHSCT that normalizes after one year while astrocyte activation appears increased beyond that, and increased serum CXCL10 likely does not reflect inflammation within the central nervous system (CNS) but rather occurs in the context of CMV reactivation or other infections post-aHSCT.